

Table 3 Factors associated with NRM in current sample and subsamples: Univariate analysis

Variable	Whole sample no (%)	Standardized difference (%) / original report	Whole sample N=286		Adults, no FD, no drepanocytosis, no thalassemia N=223	
			HR (95%CI)	P-value	HR (95%CI)	P-value
Age						
< 15	57 (20)		1		NA	
15-25	56 (20)		0.58 (0.21 – 1.55)	0.27	1	
25-40	67 (23)		0.71 (0.30 – 1.67)	0.43	1.00 (0.36 – 2.82)	0.99
40-50	49 (17)		1.34 (0.60 – 2.99)	0.47	2.16 (0.82 – 5.67)	0.12
≥ 50	57 (20)		1.21 (0.54 – 2.70)	0.64	1.90 (0.72 – 5.00)	0.19
Age < 15 or ≥ 40	163 (57)		1.80 (1.00 – 3.24)	0.049	2.01 (1.07 – 3.80)	0.031
Female gender	117 (41)		0.96 (0.55 – 1.66)	0.88	0.82 (0.43 – 1.56)	0.54
Malignant disease	251 (88)		2.83 (0.88 – 9.08)	0.080	0.98 (0.24 – 4.05)	0.97
Cell source						
BM	123 (43)		1		1	
PBSC	124 (43)		1.08 (0.58 – 1.99)	0.81	0.95 (0.50 – 1.83)	0.89
CB	39 (14)		2.55 (1.24 – 5.22)	0.011	1.96 (0.65 – 5.89)	0.23
Donor type						
Matched related	149 (52)		1			
Matched unrelated	63 (22)		1.76 (0.85 – 3.62)	0.13	1.42 (0.66 – 3.03)	0.37
Other	74 (26)		3.00 (1.62 – 5.55)	0.0005	2.05 (0.99 – 4.22)	0.052
Female donor to male recipient	79 (28)		0.74 (0.39 – 1.40)	0.35	0.91 (0.46 – 1.82)	0.79
Nonmyeloablative conditioning regimen	116 (41)		1.45 (0.84 – 2.48)	0.18	1.15 (0.62 – 2.13)	0.65
PAM index comorbidities						
Conditioning regimen						
Nonmyeloablative	174 (6)	87	1		1	
Non-TBI	108 (38)	10	0.71 (0.39 – 1.32)	0.28	1.04 (0.52 – 2.08)	0.92
TBI with ≤ 12 Gy	64 (22)	8	0.92 (0.46 – 1.85)	0.82	0.93 (0.42 – 2.10)	0.87
Disease risk						
Low	38 (13)	37	1		1	
Intermediate	156 (55)	56	1.33 (0.55 – 3.21)	0.53	0.46 (0.17 – 1.20)	0.11
High	92 (32)	24	1.57 (0.63 – 3.94)	0.33	0.42 (0.15 – 1.18)	0.10
Matched related donor	149 (52)	7	0.39 (0.22 – 0.68)	0.001	0.53 (0.28 – 1.00)	0.050
Serum creatinine level > 1.2 mg/dL	5 (2)	35	2.23 (0.54 – 9.14)	0.27	2.23 (0.54 – 9.24)	0.27
Serum ALT level > 49 U/L	110 (38)	39	0.79 (0.45 – 1.39)	0.42	0.73 (0.38 – 1.39)	0.34
CCI comorbidities						
Congestive heart failure	9 (3)	ND	1.19 (0.29 – 4.87)	0.81	1.19 (0.29 – 4.95)	0.81
Cerebrovascular disease	19 (7)	ND	0.24 (0.03 – 1.77)	0.16	0.50 (0.07 – 3.64)	0.49
Hepatic disease (only mild in the cohort)	16 (6)	ND	2.55 (1.09 – 5.97)	0.031	2.76 (1.08 – 7.06)	0.033
Solid tumor without metastases	7 (2)	ND	1.65 (0.40 – 6.77)	0.49	1.67 (0.40 – 6.88)	0.48
HCT-CI comorbidities						
Cardiac	17 (6)	4	1.18 (0.43 – 3.28)	0.75	1.28 (0.45 – 3.58)	0.64
Cerebrovascular disease	19 (7)	ND	0.24 (0.03 – 1.77)	0.16	0.50 (0.07 – 3.64)	0.49
Psychiatric disturbance	13 (4)	20	1.39 (0.43 – 4.46)	0.58	1.41 (0.44 – 4.56)	0.57
Hepatic disease						
Mild	91 (32)	38	0.73 (0.39 – 1.35)	0.31	0.77 (0.39 – 1.56)	0.48
Moderate/severe	45 (16)	41	0.73 (0.33 – 1.59)	0.43	1.23 (0.50 – 3.02)	0.65
Infection	67 (23)	58	1.15 (0.62 – 2.12)	0.66	1.10 (0.54 – 2.24)	0.80
Heart valve disease	13 (4)	12	1.33 (0.41 – 4.27)	0.63	1.39 (0.43 – 4.54)	0.58
Solid tumor	7 (2)	0	1.65 (0.40 – 6.77)	0.49	1.67 (0.40 – 6.88)	0.48

ND no or insufficient data to compare with